ArticleDrug design, development and therapy2025
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Wine-Processed Cornus officinalis Ameliorates Osteoarthritis via Modulating M1/M2 Macrophage Polarization.Journal of cellular and molecular medicine · 2026Article
- Targeting SOD3-Mediated Oxidative Stress with Betulonic Acid Protects Against Steroid-Induced Femoral Head Necrosis.Drug design, development and therapy · 2026Article
- Multifaceted mechanistic exploration ofFrontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Steroid-related osteonecrosis of the femoral head (SONFH) is bone death resulting from the use of chronic glucocorticoids. Due to its high incidence and lack of effective treatment, which is still a challenging problem in orthopedic surgery. Cornus officinalis (SZY) is usually used as a traditional use for the treatment of SONFH and plays a major role in traditional prescriptions, however, the specific pharmacological mechanisms of action remain unclear. This study is to investigate the mechanisms of SZY against SONFH via network pharmacology and experimental validation analysis. Methods: The active components and related targets of SZY and related-SONFH targets were collected from public databases. The protein-protein interaction (PPI) network, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were performed to predict the core targets and pathways of SZY in the treatment of SONFH. Then, AutoDock Vina was used for molecular docking verification. Finally, the reliability of the network pharmacology prediction results was verified through a mice SONFH model in vivo experiment. Results: Through the identification of common targets between the active components of SZY and targets related to SONFH, a total of 66 shared targets were identified. The topological analysis of the PPI network identified nine key targets. GO and KEGG enrichment analyses showed that SZY treatment for SONFH mainly include apoptosis and IL-17 signaling pathways. Molecular docking and molecular dynamics simulations results indicated that the active components in SZY exhibited high affinity for these targets. Animal experiments demonstrated that SZY reduced femoral head damage in SONFH mice, significantly downregulating TNF (p<0.01) and IL-6 (p<0.05) and modulating Bcl-2/Caspase-3 expression. Conclusion: Our study provides preclinical evidence that SZY alleviates SONFH by suppressing inflammation and apoptosis, supporting its traditional use and informing further translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.